etoposide has been researched along with gl 331 in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YC; Hu, H; Lee, KH; Liu, SY; Wang, ZQ | 1 |
| Chen, HX; Cheng, YC; Hu, H; Lee, KH; Wang, ZQ | 1 |
| Chen, HX; Cheng, YC; Guo, X; Lee, KH; Shen, YC; Wang, ZQ; Zhang, YL | 1 |
| Chang, JY; Chen, HX; Cheng, YC; Lee, KH; Wang, ZQ; Zhou, XM | 1 |
| Bowen, JP; Chang, JY; Cheng, YC; Han, FS; Kuo, YH; Lee, KH; Liu, SY; Schnur, D; Wang, ZQ | 1 |
| Cheng, YC; Cho, SJ; Lee, KH; Suffness, M; Tropsha, A | 1 |
| Bastow, KF; Cheng, YC; Cho, SJ; Kashiwada, Y; Lee, KH | 1 |
| Bastow, KF; Cheng, HH; Cheng, YC; Cho, SJ; Guan, J; Gurwith, M; Lee, KH; Tachibana, Y; Zhu, XK | 1 |
| Bastow, KF; Huang, ES; Lee, KH; Tachibana, Y; VanVliet, DS | 1 |
| Feng, J; Golbraikh, A; Lee, KH; Tropsha, A; Xiao, YD; Xiao, Z | 1 |
| Bastow, KF; Han, S; Lee, KH; Xiao, Z | 1 |
| Bastow, KF; Chen, MS; Lee, KH; Shi, Q; Sidwell, RS; Vance, JR; Wang, HK; Xiao, Z | 1 |
| Lee, KH | 1 |
| Diao, Q; Gao, F; Gao, M; Sun, Z; Wang, P; Xiao, J | 1 |
| Chao, Y; Chen, LL; Chen, LT; Chen, MH; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J; Yuan, CC | 1 |
| Chen, LT; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J | 1 |
| Chao, Y; Chen, LT; Huang, TS; Shu, CH | 1 |
| Huang, TS; Lee, CC | 1 |
| Chen, LL; Huang, HC; Huang, TS; Lee, CC; Lin, S | 1 |
| Chang, JY; Chao, Y; Chen, JD; Chen, LT; Lan, C; Li, AF; Lin, WC; Liu, JM; Liu, TS; Shiah, HS; Whang-Peng, J; Wu, CW; Wu, HW | 1 |
| Chang, AC; Chao, CC; Chu, YW; Huang, TS; Jou, YS; Lee, CC; Lin, S; Whang-Peng, J; Wu, CW | 1 |
| Chang, H; Hsien Lee, Y; Lee, CC; Lin, S; Shyu, KG; Tsai, SC; Wang, BW | 1 |
| Chen, XG; Liu, GT; Sun, H; Wang, YJ; Xiao, ZY | 1 |
2 review(s) available for etoposide and gl 331
| Article | Year |
|---|---|
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
Topics: Anti-HIV Agents; Biological Factors; Drug Design; Molecular Structure; Pharmaceutical Preparations; Plants, Medicinal | 2010 |
Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Molecular Structure; Podophyllotoxin; Stereoisomerism; Structure-Activity Relationship | 2020 |
1 trial(s) available for etoposide and gl 331
| Article | Year |
|---|---|
Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 2002 |
20 other study(ies) available for etoposide and gl 331
| Article | Year |
|---|---|
Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2'-chloro derivatives of etoposide and 4 beta-(arylamino)-4'-O-demethylpodophyllotoxins.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; DNA Damage; Etoposide; Humans; KB Cells; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Succinimides; Topoisomerase II Inhibitors | 1992 |
Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line; Cell Survival; DNA Damage; Etoposide; Humans; KB Cells; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1992 |
Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
Topics: Antineoplastic Agents, Phytogenic; DNA; DNA Damage; DNA, Neoplasm; Humans; KB Cells; Podophyllotoxin; Topoisomerase II Inhibitors | 1992 |
Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
Topics: Enzyme Inhibitors; Humans; Podophyllotoxin; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1991 |
Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
Topics: Antineoplastic Agents; Chemical Phenomena; Chemistry; Humans; Podophyllotoxin; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1990 |
Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach.
Topics: Antineoplastic Agents; Computer Graphics; DNA; DNA Topoisomerases, Type I; Models, Molecular; Molecular Conformation; Molecular Structure; Nucleic Acid Conformation; Podophyllotoxin; Structure-Activity Relationship | 1996 |
Antitumor agents. 164. Podophenazine, 2'',3''-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cell Division; DNA; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Etoposide; Humans; KB Cells; Molecular Structure; Phenazines; Podophyllotoxin; Topoisomerase II Inhibitors | 1996 |
Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Inhibitory Concentration 50; Leukemia P388; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Chlorocebus aethiops; DNA; Drug Design; Drug Screening Assays, Antitumor; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Podophyllotoxin; Structure-Activity Relationship; Tumor Cells, Cultured; Vero Cells | 2001 |
Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method.
Topics: Antineoplastic Agents; Models, Molecular; Podophyllotoxin; Quantitative Structure-Activity Relationship | 2002 |
Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; DNA Damage; Enzyme Inhibitors; Etoposide; Humans; KB Cells; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
Antitumor agents. 234. Design, synthesis, and biological evaluation of novel 4beta-[(4' '-benzamido)-amino]-4'-o-demethyl-epipodophyllotoxin derivatives.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Stability; In Vitro Techniques; Microsomes, Liver; Podophyllotoxin; Rats; Serum; Solubility; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Tumor Cells, Cultured | 1999 |
In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Etoposide; Fluorouracil; Nasopharyngeal Neoplasms; Toxicity Tests; Tumor Cells, Cultured | 2000 |
Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Calcium-Binding Proteins; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cyclin B; Cyclin B1; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Antagonism; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Etoposide; Flow Cytometry; Fungal Proteins; Humans; Nasopharyngeal Neoplasms; Nuclear Proteins; Paclitaxel; Precipitin Tests; Protein Kinases; Tetrazolium Salts; Thiazoles; Toxicity Tests; Tumor Cells, Cultured | 2001 |
A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Humans; Intercalating Agents; Telomerase; Telomere; Tumor Cells, Cultured | 2001 |
GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription.
Topics: Antineoplastic Agents, Phytogenic; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Down-Regulation; Etoposide; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Enzymologic; Genes, Reporter; Humans; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Microsatellite Repeats; Promoter Regions, Genetic; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2003 |
GL331 inhibits HIF-1alpha expression in a lung cancer model.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Models, Biological; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2003 |
Induction of cell cycle arrest by GL331 via triggering an ATM-dependent DNA damage response in HepG2 cells.
Topics: Cell Cycle; Cell Cycle Checkpoints; DNA Damage; Etoposide; Hep G2 Cells; Histones; Humans; Molecular Structure; Topoisomerase II Inhibitors | 2012 |